Exelixis, Inc. (EXEL) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended July 4, 2025 (referred to as June 30, 2025, for convenience). Exelixis is an oncology company focused on the discovery, development, and commercialization of medicines for difficult-to-treat cancers. The company's revenue is primarily driven by its flagship molecule, cabozantinib, marketed as CABOMETYX and COMETRIQ. The company also holds collaborations for the international commercialization of cabozantinib with Ipsen (outside U.S. and Japan) and Takeda (Japan).
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenues | $568,261 | $637,178 | $1,123,708 | $1,062,404 |
| Net Product Revenues | $520,014 | $437,581 | $1,033,297 | $816,104 |
| Collaboration Revenues | $48,247 | $199,597 | $90,411 | $246,300 |
| Net Income | $184,848 | $226,116 | $344,464 | $263,433 |
| Diluted EPS | $0.65 | $0.77 | $1.20 | $0.88 |
| Operating Cash Flow (YTD) | $260,430 | $188,370 | - | - |
| Cash & Marketable Securities | $1,385,750 | - | - | - |
| Debt | $0 | $0 | - | - |
Note: The company reported no long-term debt. Gross margin for net product revenues remained stable at approximately 96%.
Material Changes vs. Prior Period
- Revenue Mix Shift: Total revenue decreased 11% in Q2 2025 compared to Q2 2024, primarily due to a 76% drop in collaboration revenues. This decline was driven by the absence of a $150 million commercial milestone payment from Ipsen recognized in Q2 2024. Conversely, net product revenues increased 19% year-over-year, driven by a 20% increase in CABOMETYX unit sales.
- Profitability: Net income decreased 18% in Q2 2025 ($184.8M vs. $226.1M) due to the lower collaboration revenue, despite a reduction in the effective tax rate (19.8% vs. 22.8%).
- Operating Expenses: Research and Development (R&D) expenses decreased 5% to $200.4M, driven by lower clinical trial and manufacturing costs, partially offset by higher stock-based compensation. Selling, General, and Administrative (SG&A) expenses increased 2% to $134.9M due to higher personnel and marketing costs.
- Capital Allocation: The company aggressively returned capital to shareholders, repurchasing 7.5 million shares in Q2 2025 for $303.8 million. YTD 2025 repurchases totaled $796.3 million.
Guidance, Outlook, and Risks
- Pipeline Progress: The company announced positive top-line results from the STELLAR-303 trial for zanzalintinib (in combination with atezolizumab) in colorectal cancer, showing statistically significant improvement in overall survival. The company intends to file a New Drug Application (NDA) based on these results.
- Commercial Outlook: Management projects net product revenues may increase for the remainder of 2025, supported by the Q1 2025 FDA approval of CABOMETYX for neuroendocrine tumors (NET). Collaboration services revenues are projected to decrease due to lower development cost reimbursements and higher royalty payments to Royalty Pharma.
- Regulatory & Legal Risks:
- Patent Litigation: The company is engaged in ongoing litigation regarding generic versions of CABOMETYX. A settlement with Biocon was reached in July 2025, granting a license to market a generic version starting January 1, 2031. Litigation with MSN is on appeal at the Federal Circuit, and litigation with Sun and Azurity is ongoing.
- IRA Impact: The company qualifies for the "small biotech exception" under the Inflation Reduction Act through 2027, exempting cabozantinib from Medicare price negotiation through that period.
- Liquidity: With $1.4 billion in cash and marketable securities, the company expects sufficient liquidity to fund operations for at least 12 months and beyond.
Key Facts for Investor Verification
- Revenue Sustainability: Verify the trajectory of net product revenue growth (CABOMETYX) to ensure it can offset the volatility of collaboration milestone revenues.
- Patent Expiration Timeline: Confirm the specific dates of patent expirations for CABOMETYX in the U.S. (currently protected until 2030/2032 based on litigation outcomes) and the impact of the Biocon settlement.
- Zanzalintinib NDA Filing: Monitor the timeline for the submission of the NDA for zanzalintinib following the positive STELLAR-303 results.
- Stock Repurchase Run Rate: Assess the remaining $203.7 million authorization under the current buyback program and the potential for future authorizations given the strong cash flow.
- Discounts and Allowances: Review the trend in chargebacks and rebates, which increased 35% in Q2 2025, as this directly impacts net product revenue margins.